My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 571

    1.

    Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis.

    Lee YS, Shin S, Shigihara T, Hahm E, Liu MJ, Han J, Yoon JW, Jun HS.

    Diabetes. 2007 Jun;56(6):1671-9. Epub 2007 Mar 16.PMID: 17369525 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Prolonged remission of diabetes by regeneration of beta cells in diabetic mice treated with recombinant adenoviral vector expressing glucagon-like peptide-1.

    Liu MJ, Shin S, Li N, Shigihara T, Lee YS, Yoon JW, Jun HS.

    Mol Ther. 2007 Jan;15(1):86-93.PMID: 17164779 [PubMed - indexed for MEDLINE]Related articles

    3.

    Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.

    Green BD, Lavery KS, Irwin N, O'harte FP, Harriott P, Greer B, Bailey CJ, Flatt PR.

    J Pharmacol Exp Ther. 2006 Aug;318(2):914-21. Epub 2006 Apr 28.PMID: 16648370 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.

    Ding X, Saxena NK, Lin S, Gupta NA, Anania FA.

    Hepatology. 2006 Jan;43(1):173-81. Erratum in: Hepatology. 2006 Aug;44(2):515. Gupta, Narita [corrected to Gupta, Nitika Arora]. PMID: 16374859 [PubMed - indexed for MEDLINE]Related articles

    5.

    Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes.

    Parsons GB, Souza DW, Wu H, Yu D, Wadsworth SG, Gregory RJ, Armentano D.

    Gene Ther. 2007 Jan;14(1):38-48. Epub 2006 Aug 24.PMID: 16929351 [PubMed - indexed for MEDLINE]Related articles

    6.

    Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action.

    Scrocchi LA, Hill ME, Saleh J, Perkins B, Drucker DJ.

    Diabetes. 2000 Sep;49(9):1552-60.PMID: 10969840 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.

    Lee Y, Kwon MK, Kang ES, Park YM, Choi SH, Ahn CW, Kim KS, Park CW, Cha BS, Kim SW, Sung JK, Lee EJ, Lee HC.

    J Gene Med. 2008 Mar;10(3):260-8.PMID: 18085721 [PubMed - indexed for MEDLINE]Related articles

    8.

    Acute intravenous leptin infusion increases glucose turnover but not skeletal muscle glucose uptake in ob/ob mice.

    Burcelin R, Kamohara S, Li J, Tannenbaum GS, Charron MJ, Friedman JM.

    Diabetes. 1999 Jun;48(6):1264-9.PMID: 10342814 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice.

    Grefhorst A, van Dijk TH, Hammer A, van der Sluijs FH, Havinga R, Havekes LM, Romijn JA, Groot PH, Reijngoud DJ, Kuipers F.

    Am J Physiol Endocrinol Metab. 2005 Nov;289(5):E829-38. Epub 2005 Jun 7.PMID: 15941783 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor.

    Cani PD, Knauf C, Iglesias MA, Drucker DJ, Delzenne NM, Burcelin R.

    Diabetes. 2006 May;55(5):1484-90.PMID: 16644709 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle.

    Kaidanovich-Beilin O, Eldar-Finkelman H.

    J Pharmacol Exp Ther. 2006 Jan;316(1):17-24. Epub 2005 Sep 16.PMID: 16169938 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.

    Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E, Benhamed F, Grémeaux T, Drucker DJ, Kahn CR, Girard J, Tanti JF, Delzenne NM, Postic C, Burcelin R.

    J Clin Invest. 2005 Dec;115(12):3554-63.PMID: 16322793 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.

    Parker JC, Lavery KS, Irwin N, Green BD, Greer B, Harriott P, O'Harte FP, Gault VA, Flatt PR.

    J Endocrinol. 2006 Oct;191(1):93-100.PMID: 17065392 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.

    Green BD, Irwin N, Gault VA, Bailey CJ, O'Harte FP, Flatt PR.

    J Endocrinol. 2005 May;185(2):307-17.PMID: 15845923 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice.

    Liang Y, Osborne MC, Monia BP, Bhanot S, Watts LM, She P, DeCarlo SO, Chen X, Demarest K.

    Metabolism. 2005 Jul;54(7):848-55.PMID: 15988691 [PubMed - indexed for MEDLINE]Related articles

    16.

    Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.

    Green BD, Irwin N, Duffy NA, Gault VA, O'harte FP, Flatt PR.

    Eur J Pharmacol. 2006 Oct 10;547(1-3):192-9. Epub 2006 Jul 27.PMID: 16945366 [PubMed - indexed for MEDLINE]Related articles

    17.

    Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.

    Irwin N, McClean PL, Flatt PR.

    J Pept Sci. 2007 Jun;13(6):400-5.PMID: 17486662 [PubMed - indexed for MEDLINE]Related articles

    18.

    Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.

    Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JR, Girard J, Postic C.

    Diabetes. 2006 Aug;55(8):2159-70.PMID: 16873678 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

    Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M.

    Diabetes. 1999 May;48(5):1026-34.PMID: 10331407 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.

    Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H.

    Eur J Pharmacol. 2008 Jul 7;588(2-3):325-32. Epub 2008 Apr 10.PMID: 18499100 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity